Supplementary Figure S4 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy

Key Points

• Sustained myeloid recovery is significantly influenced by clonal hematopoiesis and baseline ferritin levels post-CAR T-cell therapy.
• The adjusted hazard ratio for myeloid recovery indicates a notable correlation with both baseline ferritin levels and the specific genetic mutations involved.
• Assessment incorporates multivariable models considering age, previous treatments, and cytogenetic abnormalities to refine results.
• Findings may enable better risk stratification for hematologic toxicity and guide treatment protocols in future CAR T-cell therapies.